Targeted Ligand-Payload Delivery for Controllable Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cell therapies, such as CAR T cell and stem cell-based regenerative therapies, face challenges in controlling the activity of transplanted cells, managing side effects like cytokine storms, and addressing tumorigenic potential.
Innovation Solution
A drug delivery platform that utilizes an engineered protein on target cells for transplant, comprising a fusion protein with a non-membrane protein and a membrane-anchored peptide, conjugated with a high-affinity ligand and a payload drug. The small ligand binds to the engineered protein, facilitating internalization of the payload, which can be released to modulate cell therapy effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cells are used to treat leukemia, then therapeutic efficacy is improved, but harmful side effects such as cytokine storm and killing of normal B cells occur
Solution Approach 1:
The patent introduces a dimerizable FKBP domain as an intermediary control mechanism. By fusing FKBP to the CAR T cell receptor and using a dimeric FK506 ligand, the system creates a controllable intermediary step between drug administration and T cell activation. This allows external control of the harmful cytokine storm effect while preserving therapeutic efficacy through precise temporal and spatial regulation of T cell activation.
2Productivity
If CAR T cells proliferate rapidly to kill tumor cells, then anti-tumor activity is improved, but control over transplanted cell activity is reduced
Solution Approach 1:
The patent implements dynamic control of CAR T cell activity through a reversible dimerization mechanism. The FKBP-FK506 interaction allows the system to transition between active and inactive states on demand. By administering the dimeric FK506 ligand, clinicians can dynamically activate or deactivate T cell proliferation and cytotoxic activity, providing real-time control over transplanted cell behavior while maintaining high productivity when needed.
3Reliability
If stem cells are transplanted for regenerative therapy, then tissue regeneration is improved, but tumorigenic potential of transplanted cells increases
Solution Approach 1:
The patent applies the FKBP-FK506 dimerization system as an intermediary safety mechanism for stem cell transplantation. By incorporating the FKBP domain into stem cell constructs and using controllable dimeric ligands, the system creates an external control layer that can regulate stem cell behavior. This allows promotion of beneficial regenerative effects while suppressing harmful tumorigenic potential through precise spatial and temporal control of stem cell activation and differentiation.
4Object-affected harmful factors
If a control mechanism is added to regulate transplanted cell activity, then safety is improved, but device complexity increases
Solution Approach 1:
The patent extracts the control mechanism from the cellular therapy itself and places it in the external ligand domain. By separating the FKBP domain (integrated into cells) from the dimeric FK506 ligand (administered externally), the system reduces cellular complexity while maintaining safety control. The complex control logic is relocated to the pharmacological agent rather than the engineered cell, simplifying the biological construct while preserving regulatory capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This platform allows for precise control of transplanted cell activity, reducing side effects and enhancing therapeutic efficacy by delivering specific payloads directly to the cells, thereby fine-tuning cell therapy outcomes.
Implementation Method 1
at least one small ligand has intrinsic high affinity to at least one component of the engineered protein; the small ligand binds to the engineered protein, facilitating internalization of the payload
Data Source
AI summary
A drug delivery platform providing flexible fine tune of cell therapy is disclosed herein. Particularly, an engineered fusion protein is coupled with a high affinity ligand carrying at least one payload of drug to be internalized by the transplanted cell to observe or regulate transplanted cell therapy effects.